Favorable-Risk RCC: Options for VEGF TKI Monotherapy

Favorable-Risk RCC: Options for VEGF TKI Monotherapy

Comparing IO/TKI and TKI monotherapy for kidney cancerПодробнее

Comparing IO/TKI and TKI monotherapy for kidney cancer

Favorable-Risk RCC: Frontline VEGF TKI/IO CombinationsПодробнее

Favorable-Risk RCC: Frontline VEGF TKI/IO Combinations

Treatment of Favorable Risk Renal Cell CarcinomaПодробнее

Treatment of Favorable Risk Renal Cell Carcinoma

Which Patients With RCC Are Right for Monotherapy?Подробнее

Which Patients With RCC Are Right for Monotherapy?

VEGF TKI Therapy in the Adjuvant Setting of RCCПодробнее

VEGF TKI Therapy in the Adjuvant Setting of RCC

Dr. Figlin on Toxicity Profile of Immunotherapy/VEGF TKI Combinations in RCCПодробнее

Dr. Figlin on Toxicity Profile of Immunotherapy/VEGF TKI Combinations in RCC

VEGF-TKI Therapy in First-Line mRCCПодробнее

VEGF-TKI Therapy in First-Line mRCC

The Role of Tyrosine Kinase Inhibitors and mTOR InhibitorsПодробнее

The Role of Tyrosine Kinase Inhibitors and mTOR Inhibitors

Dr. Alva on TKI Monotherapy and Combinations for RCCПодробнее

Dr. Alva on TKI Monotherapy and Combinations for RCC

Second-Line Treatment Options for Advanced RCCПодробнее

Second-Line Treatment Options for Advanced RCC

Optimizing Patient Outcomes in RCC Through Safe Use of Immuno-Oncology and Targeted ApproachesПодробнее

Optimizing Patient Outcomes in RCC Through Safe Use of Immuno-Oncology and Targeted Approaches

RCC MasterClass and Clinical Consult: Novel Immune and Targeted TherapiesПодробнее

RCC MasterClass and Clinical Consult: Novel Immune and Targeted Therapies

Poor-Risk Advanced RCC: TKI Therapy & OutlookПодробнее

Poor-Risk Advanced RCC: TKI Therapy & Outlook

Immunotherapy Combinations Improve Survival in Advanced Renal Cell CarcinomaПодробнее

Immunotherapy Combinations Improve Survival in Advanced Renal Cell Carcinoma

Expert Guidance on Leveraging Therapeutic Strategies in RCCПодробнее

Expert Guidance on Leveraging Therapeutic Strategies in RCC

Clinically Meaningful Outcomes Among Expanding Treatment Options in RCCПодробнее

Clinically Meaningful Outcomes Among Expanding Treatment Options in RCC

Will immunotherapy take over the treatment landscape of patients high-risk renal cell carcinoma?Подробнее

Will immunotherapy take over the treatment landscape of patients high-risk renal cell carcinoma?

Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCCПодробнее

Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCC

Choosing an IO/TKI Doublet for RCC Patients: Efficacy Data, Dosing, and MoreПодробнее

Choosing an IO/TKI Doublet for RCC Patients: Efficacy Data, Dosing, and More